AZN
Price
$77.57
Change
-$0.48 (-0.61%)
Updated
Sep 16, 04:59 PM (EDT)
Capitalization
247.87B
51 days until earnings call
NVS
Price
$122.79
Change
-$0.52 (-0.42%)
Updated
Sep 16, 12:33 PM (EDT)
Capitalization
236.85B
42 days until earnings call
Interact to see
Advertisement

AZN vs NVS

Header iconAZN vs NVS Comparison
Open Charts AZN vs NVSBanner chart's image
AstraZeneca
Price$77.57
Change-$0.48 (-0.61%)
Volume$64.74K
Capitalization247.87B
Novartis AG
Price$122.79
Change-$0.52 (-0.42%)
Volume$2.35K
Capitalization236.85B
AZN vs NVS Comparison Chart in %
Loading...
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AZN vs. NVS commentary
Sep 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a Buy and NVS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 16, 2025
Stock price -- (AZN: $78.05 vs. NVS: $123.31)
Brand notoriety: AZN: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AZN: 101% vs. NVS: 74%
Market capitalization -- AZN: $247.87B vs. NVS: $236.85B
AZN [@Pharmaceuticals: Major] is valued at $247.87B. NVS’s [@Pharmaceuticals: Major] market capitalization is $236.85B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $670.72B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZN’s FA Score shows that 1 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • AZN’s FA Score: 1 green, 4 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, both AZN and NVS are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZN’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).

  • AZN’s TA Score: 4 bullish, 4 bearish.
  • NVS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both AZN and NVS are a good buy in the short-term.

Price Growth

AZN (@Pharmaceuticals: Major) experienced а -4.30% price change this week, while NVS (@Pharmaceuticals: Major) price change was -4.20% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.10%. For the same industry, the average monthly price growth was +0.56%, and the average quarterly price growth was +10.73%.

Reported Earning Dates

AZN is expected to report earnings on Nov 06, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.10% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AZN($248B) and NVS($237B) have the same market capitalization . AZN has higher P/E ratio than NVS: AZN (29.40) vs NVS (17.98). NVS YTD gains are higher at: 31.281 vs. AZN (21.666). NVS has higher annual earnings (EBITDA): 22.7B vs. AZN (16.8B). AZN (7.11B) and NVS (7B) have equal amount of cash in the bank . NVS (32.6B) and AZN (32.8B) have identical debt. AZN (56.5B) and NVS (55.2B) have equivalent revenues.
AZNNVSAZN / NVS
Capitalization248B237B105%
EBITDA16.8B22.7B74%
Gain YTD21.66631.28169%
P/E Ratio29.4017.98164%
Revenue56.5B55.2B102%
Total Cash7.11B7B102%
Total Debt32.8B32.6B101%
FUNDAMENTALS RATINGS
AZN vs NVS: Fundamental Ratings
AZN
NVS
OUTLOOK RATING
1..100
7281
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
15
Undervalued
PROFIT vs RISK RATING
1..100
3915
SMR RATING
1..100
4629
PRICE GROWTH RATING
1..100
5452
P/E GROWTH RATING
1..100
7878
SEASONALITY SCORE
1..100
6565

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (15) in the Pharmaceuticals Major industry is in the same range as AZN (22). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.

NVS's Profit vs Risk Rating (15) in the Pharmaceuticals Major industry is in the same range as AZN (39). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.

NVS's SMR Rating (29) in the Pharmaceuticals Major industry is in the same range as AZN (46). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.

NVS's Price Growth Rating (52) in the Pharmaceuticals Major industry is in the same range as AZN (54). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.

NVS's P/E Growth Rating (78) in the Pharmaceuticals Major industry is in the same range as AZN (78). This means that NVS’s stock grew similarly to AZN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AZNNVS
RSI
ODDS (%)
Bearish Trend 2 days ago
43%
Bearish Trend 2 days ago
47%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
40%
Momentum
ODDS (%)
Bearish Trend 2 days ago
56%
Bearish Trend 2 days ago
49%
MACD
ODDS (%)
Bearish Trend 2 days ago
36%
Bearish Trend 2 days ago
39%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
45%
Bearish Trend 2 days ago
43%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
55%
Bullish Trend 2 days ago
46%
Advances
ODDS (%)
Bullish Trend 14 days ago
55%
Bullish Trend 12 days ago
49%
Declines
ODDS (%)
Bearish Trend 2 days ago
43%
Bearish Trend 2 days ago
45%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
52%
Bullish Trend 2 days ago
50%
Aroon
ODDS (%)
Bullish Trend 2 days ago
52%
Bullish Trend 2 days ago
41%
View a ticker or compare two or three
Interact to see
Advertisement
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DUSL72.420.75
+1.05%
Direxion Dly Industrials Bull 3X ShsETF
OEF330.472.55
+0.78%
iShares S&P 100 ETF
GGN5.020.03
+0.60%
GAMCO Global Gold Natural Resources & Income Trust
ACLC76.860.25
+0.33%
American Century Large Cap Equity ETF
BSL14.12-0.01
-0.04%
Blackstone Senior Floating Rate 2027 Term Fund

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
-0.65%
GSK - NVS
67%
Closely correlated
-1.30%
AZN - NVS
60%
Loosely correlated
-1.90%
PFE - NVS
58%
Loosely correlated
+0.42%
JNJ - NVS
54%
Loosely correlated
-0.37%
SNY - NVS
50%
Loosely correlated
-0.87%
More